A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

Han Boram; Jung Joo Young; Kim Hyeong Su; Cho Ji Woong; Kim Kab Choong; Lim Hyun; Kang Ho Suk; Ha Hong Il; Kim Min-Jeong; Kim Jung Hoon; Choi Dae Ro; Jang Geundoo; Kim Jung Han; Song Hunho; Zang Dae Young

首页> 外文期刊>Cancer chemotherapy and pharmacology. >A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

【24h】

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

机译：奥沙利铂，伊立替康和S-1（OIS）在转移性或复发性胃肠道肿瘤患者中的剂量寻找研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined oxaliplatin, irinotecan, and S-1 chemotherapy for metastatic or recurrent gastrointestinal (GI) cancer.

机译：为了确定最大耐受剂量（MTD），推荐剂量（RD）以及奥沙利铂，伊立替康和S-1化疗联合治疗转移性或复发性胃肠道（GI）癌症的活性。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2016年第5期|共10页
作者
Han Boram; Jung Joo Young; Kim Hyeong Su; Cho Ji Woong; Kim Kab Choong; Lim Hyun; Kang Ho Suk; Ha Hong Il; Kim Min-Jeong; Kim Jung Hoon; Choi Dae Ro; Jang Geundoo; Kim Jung Han; Song Hunho; Zang Dae Young;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Gastrointestinal cancer; Oxaliplatin; Irinotecan; S-1; Maximum tolerated dose;

机译：胃肠道癌;奥沙利铂;伊立替康;S-1;最大耐受剂量;

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer [J] . Han Boram, Jung Joo Young, Kim Hyeong Su, Cancer chemotherapy and pharmacology. . 2016,第5期

机译：奥沙利铂，伊立替康和S-1（OIS）在转移性或复发性胃肠道肿瘤患者中的剂量寻找研究
3. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9 [J] . Stine Braendegaard Winther, Pia ?sterlund, ?ke Berglund, BMC Cancer . 2017,第1期

机译：随机研究比较全剂量单药治疗（S-1，然后伊立替康）和降低剂量联合治疗（S-1 /奥沙利铂，然后S-1 /伊立替康）作为老年转移性大肠癌患者的初始治疗：NORDIC 9
4. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. [J] . Yasui H, Yoshino T, Boku N, Japanese journal of clinical oncology. . 2009,第5期

机译：氟嘧啶和伊立替康或氟嘧啶，伊立替康和奥沙利铂治疗失败后转移性结直肠癌患者S-1单一疗法的回顾性分析。
5. HIFU for Treating Patients with Advanced Recurrent / Metastatic Cancerin Pelvis: A Preliminary Clinical Study [C] . The 3rd Asian congress on hyperthermic oncology and the 9th Chineses symposium on hyperthermic oncology . 2002

机译：HIFU治疗晚期骨盆癌复发/转移性癌症的初步临床研究
6. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
7. Multicenter Phase II Study of Oxaliplatin Irinotecan and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer [O] . Changhoon Yoo, Boram Han, Hyeong Su Kim, 2018

机译：奥沙利铂伊立替康和S-1作为复发或转移性胆道癌患者的一线治疗的多中心II期研究
8. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer : NORDIC 9 [O] . Winther, Stine Braendegaard, Österlund, Pia, Berglund, Åke, 2017

机译：随机研究比较了全剂量单药治疗（S-1，然后伊立替康）和减剂量联合治疗（S-1 /奥沙利铂，然后S-1 /伊立替康）作为老年转移性大肠癌患者的初始治疗的方法：NORDIC 9

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

摘要

著录项

相似文献

相关主题

期刊订阅